Seoul, South Korea · Founded 2021 · Privately Held (backing)
Developer of protein-based therapeutics designed for the treatment of intractable neurodegenerative diseases. Illimis Therapeutics is based in Seoul, South Korea and was founded in 2021. It has raised $64.3 million.
Last price · $/share
—
Implied valuation
—
Total raised
$64.3M
Last round
—
Team — not yet on record
No current team members for Illimis Therapeutics are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Illimis Therapeutics with a free account
·The complete investor list: 27 names
·Watch Illimis Therapeutics: the Monday email on marks, rounds and moves
